Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | RORC | P51449 | 2/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3476912 | 0.89 | NR1H2 (0.39) | USP2SMN1; SMN2NR1H2GPR119RORC | |
| SCHEMBL571118 | 0.87 | USP2 (0.46) | USP2SMN1; SMN2HPGDEPHX2GPR119 | |
| SCHEMBL26409745 | 0.85 | USP2 (0.46) | USP2SMN1; SMN2NR1H2HPGDEPHX2 | |
| SCHEMBL30694561 | 0.84 | SCD5 (0.40) | USP2SMN1; SMN2NR1H2HPGDEPHX2 | |
| SCHEMBL22405855 | 0.84 | HPGD (0.44) | USP2SMN1; SMN2HPGDEPHX2GPR119 | |
| SCHEMBL13958033 | 0.82 | USP2 (0.47) | USP2SMN1; SMN2NR1H2HPGDEPHX2 | |
| SCHEMBL22118612 | 0.81 | USP2 (0.43) | USP2SMN1; SMN2NR1H2HPGDEPHX2 | |
| SCHEMBL4298314 | 0.81 | USP2 (0.51) | USP2SMN1; SMN2HPGDEPHX2GPR119 | |
| SCHEMBL13419535 | 0.81 | USP2 (0.46) | USP2SMN1; SMN2NR1H2HPGDEPHX2 | |
| SCHEMBL2280402 | 0.80 | USP2 (0.48) | USP2SMN1; SMN2NR1H2HPGDEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 274 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4313980-B1 | LACTIVICIN COMPOUNDS, THEIR PREPARATION AND USE AS ANTIBACTERIAL AGENTS | FEDORA PHARMACEUTICALS INC (CA) | 2026-04-22 | — | — | EP | disclosed |
| EP-4685147-A2 | LACTIVICIN COMPOUNDS, THEIR PREPARATION AND USE AS ANTIBACTERIAL AGENTS | Fedora Pharmaceuticals Inc. (CA) | 2026-01-28 | — | — | EP | disclosed |
| US-12528804-B2 | Lactivicin compounds, their preparation and use as antibacterial agents | FEDORA PHARMACEUTICALS INC. (CA) | 2026-01-20 | — | — | US | disclosed |
| US-20250250232-A1 | AZETIDINE DERIVATIVES AND USE THEREOF AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2025-08-07 | — | — | US | disclosed |
| US-12351571-B2 | Substituted quinoxaline compounds as inhibitors of FGFR tyrosine kinases | ARRAY BIOPHARMA INC. (US) | 2025-07-08 | — | — | US | disclosed |
| US-20250100966-A1 | MEK INHIBITORS AND METHODS OF THEIR USE | EXELIXIS INC (US) | 2025-03-27 | — | — | US | disclosed |
| US-12180226-B2 | Spirotricycle RIPK1 inhibitors and methods of uses thereof | MERCK SHARP & DOHME LLC (US) | 2024-12-31 | — | — | US | disclosed |
| EP-4423096-A1 | SPIROTRICYCLE RIPK1 INHIBITORS AND METHODS OF USES THEREOF | Merck Sharp & Dohme LLC (US) | 2024-09-04 | — | — | EP | disclosed |
| EP-3604305-B1 | NOVEL PYRIDONE CARBOXYLIC ACID DERIVATIVE OR SALT THEREOF | WAKUNAGA PHARMA CO LTD (JP) | 2024-08-28 | — | — | EP | disclosed |
| CN-118488957-A | Spirotricyclic RIPK1 inhibitors and methods of use thereof | 默沙东有限责任公司 | 2024-08-13 | — | — | CN | disclosed |
| WO-2010030704-A2 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2010-03-18 | — | — | WO | disclosed |
| US-20090156576-A1 | anticarcinogenic agent; 1-({3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl}-carbonyl)azetidin-3-ol | EXELIXIS INC. (US) | 2009-06-18 | — | — | US | disclosed |
| WO-2009067692-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2009-05-28 | — | — | WO | disclosed |
| US-20080300199-A1 | ANTIBACTERIAL 1,4,5-SUBSTITUTED AMINOGLYCOSIDE ANALOGS | ACHAOGEN INC. (US) | 2008-12-04 | — | — | US | disclosed |
| US-20080300199-A1 | ANTIBACTERIAL 1,4,5-SUBSTITUTED AMINOGLYCOSIDE ANALOGS | ACHAOGEN INC. (US) | 2008-12-04 | — | — | US | disclosed |
| WO-2008124085-A2 | METHODS OF USING COMBINATIONS OF MEK AND JAK-2 INHIBITORS | EXELIXIS, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
| WO-2008124821-A1 | ANTIBACTERIAL 1,4,5-SUBSTITUTED AMINOGLYCOSIDE ANALOGS | ACHAOGEN INC. (US) | 2008-10-16 | — | — | WO | disclosed |
| US-20080166359-A1 | Methods of using MEK inhibitors | EXELIXIS, INC. | 2008-07-10 | — | — | US | disclosed |
| EP-1934174-A1 | AZETIDINES AS MEK INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Exelixis, Inc. (US) | 2008-06-25 | — | — | EP | disclosed |
| WO-2007044515-A1 | AZETIDINES AS MEK INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | EXELIXIS, INC. (US) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300199-A1 | ANTIBACTERIAL 1,4,5-SUBSTITUTED AMINOGLYCOSIDE ANALOGS | ALG8, NRDC, MRPL21 | USP2 4405/4885SMN1; SMN2 3965/4885NR1H2 3642/4885 |
| US-12180226-B2 | Spirotricycle RIPK1 inhibitors and methods of uses thereof | RIPK1, RIPK3, RIPK4 | USP2 3467/4885SMN1; SMN2 4062/4885NR1H2 685/4885 |
| US-20090156576-A1 | anticarcinogenic agent; 1-({3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl}-carbonyl)azetidin-3-ol | NRAS, BRAF, KRAS | USP2 4017/4885SMN1; SMN2 3569/4885NR1H2 1561/4885 |
| US-20250100966-A1 | MEK INHIBITORS AND METHODS OF THEIR USE | BRAF, NRAS, KRAS | USP2 4689/4885SMN1; SMN2 3747/4885NR1H2 1764/4885 |
| US-12528804-B2 | Lactivicin compounds, their preparation and use as antibacterial agents | LCT, LPO, CLSPN | USP2 1761/4885SMN1; SMN2 3073/4885NR1H2 1719/4885 |
| US-20080166359-A1 | Methods of using MEK inhibitors | BRAF, NRAS, KRAS | USP2 3592/4885SMN1; SMN2 3846/4885NR1H2 2424/4885 |
| US-20250250232-A1 | AZETIDINE DERIVATIVES AND USE THEREOF AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS | DPP9, DPP4, DPP3 | USP2 1164/4885SMN1; SMN2 2833/4885NR1H2 3487/4885 |
| US-12351571-B2 | Substituted quinoxaline compounds as inhibitors of FGFR tyrosine kinases | FGFR3, FGFR4, FGFR1 | USP2 2550/4885SMN1; SMN2 587/4885NR1H2 3292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.